| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADNCT06709014 | ANVS | Phase 3 | Active not recruiting | 2027-12Estimated |
| A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288 | IBRX | Phase 2 | Recruiting | 2027-05Estimated |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsNCT06720038 | PCVX | Phase 2 | Active not recruiting | 2027-12Estimated |
| Efficacy Study of EVO301 in Moderate to Severe Atopic DermatitisNCT06723405 | EVMN | Phase 2 | Completed | 2025-11-17Actual |
| Efficacy and Safety of VDPHL01 in Males With AGANCT06724614 | MANE | Phase 2, Phase 3 | Active not recruiting | 2026-02Estimated |
| A Study of Barzolvolimab in Patients With Atopic DermatitisNCT06727552 | Celldex Therapeutics | Phase 2 | Active not recruiting | 2026-05-06Actual |
| A Study of Lorigerlimab in Participants With Advanced Solid TumorsNCT06730347 | MacroGenics | Phase 2 | Recruiting | 2027-07Estimated |
| A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsNCT06736262 | JSPR | Phase 2 | Terminated | 2026-07-21Actual |
| An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyNCT06736509 | AXSM | Phase 3 | Terminated | 2025-02-17Actual |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574 | Cytokinetics | Phase 3 | Recruiting | 2027-09Estimated |
| A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 | Definium Therapeutics US, Inc. | Phase 3 | Active not recruiting | 2026-07-15Actual |
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyNCT06745908 | IBRX | Phase 3 | Recruiting | 2028-09Estimated |
| Avexitide for Treatment of Post-Bariatric HypoglycemiaNCT06747468 | AMLX | Phase 3 | Active not recruiting | 2026-07-08Actual |
| Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic FibrosisNCT06747858 | Arcturus Therapeutics, Inc. | Phase 2 | Recruiting | 2027-06Estimated |
| A Study of NE3107 in Early Parkinson'sNCT06757010 | BIVI | Phase 2 | Completed | 2026-05-01Actual |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 | CELC | Phase 3 | Recruiting | 2029-03-31Estimated |
| A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546 | RYTM | Phase 3 | Recruiting | 2027-03-13Estimated |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 | Summit Therapeutics | Phase 3 | Recruiting | 2028-04Estimated |
| A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683 | Alkermes, Inc. | Phase 2, Phase 3 | Recruiting | 2030-06Estimated |
| An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671 | MoonLake Immunotherapeutics AG | Phase 3 | Completed | 2026-09-28Actual |
| A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597 | RYTM | Phase 2 | Active not recruiting | 2026-11-03Actual |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerNCT06774131 | URGN | Phase 3 | Recruiting | 2027-03Estimated |
| This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsNCT06774625 | Latigo Biotherapeutics | Phase 2 | Completed | 2025-08-08Actual |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379 | XENE | Phase 3 | Terminated | 2026-10-28Actual |
| Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain MetastasesNCT06777433 | RADX | Phase 2 | Active not recruiting | 2026-04-23Actual |
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454 | MLYS | Phase 2 | Completed | 2025-12-17Actual |
| L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLNCT06788756 | MBRX | Phase 2, Phase 3 | Recruiting | 2029-08Estimated |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCNCT06788990 | Bicara Therapeutics | Phase 2, Phase 3 | Recruiting | 2028-04Estimated |
| A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)NCT06789913 | RLAY | Phase 2 | Recruiting | 2031-07Estimated |
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT06790966 | PDSB | Phase 3 | Terminated | 2026-08-25Actual |
Trial details
- Registry ID
- NCT06709014
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06710288
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06720038
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06723405
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06724614
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06727552
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06730347
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06736262
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06736509
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06736574
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06741228
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06745908
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06747468
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06747858
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06757010
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06757634
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06760546
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06767514
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06767683
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06768671
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06772597
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06774131
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06774625
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06775379
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06777433
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06785454
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06788756
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06788990
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06789913
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06790966
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.